This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
U.S. stocks close a record-setting week with mixed results, as hope builds for the economy to manage high inflation without ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
(Reuters) -The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued ...
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...